Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 7181-7190

  Zhang, Xiaoping ^a,b   Li, Wenhua ^a   Olumi, Aria F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; LEXATUMUMAB; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C FOS; RECEPTOR ANTIBODY; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

AGONIST; APOPTOSIS; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN INDUCTION; SENSITIVITY ANALYSIS; SENSITIZATION; TUMOR XENOGRAFT; UPREGULATION; XENOGRAFT;

ANDROGENS; ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PHENOTYPE; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TETRADECANOYLPHORBOL ACETATE; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION FACTOR AP-1; UP-REGULATION;

EID: 37249084581     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1133     Document Type: Article

References (48)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
2. O'Kane HF, Watson CJ, Johnston SR, Petak I, Watson RW, Williamson KE. Targeting death receptors in bladder, prostate and renal cancer. J Urol 2006;175:432-8.
3. Bodmer JL, Holler N, Reynard S, et al. TRAIL receptor-2 signals apoptosis through FADDand caspase-8. Nat Cell Biol 2000;2:241-3.
4. Ashkenazi A, Pai RC, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62.
5. Johnson RL, Gillotte D, Poortman C, et al. Human agonistic anti-TRAIL receptor antibodies, HGS-ETR1 and HGS-ETR2, induce apoptosis in ovarian tumor lines and their activity is enhanced by taxol and carboplatin. American Association of Cancer Research Annual Meeting; 2004; Orlando (FL); 2004. p. Abstract 3579.
6. Roach CM, Sharifi A, Askaa J, et al. Development of sensitive and specific immunohistochemical assays for pro-apoptotic TRAIL-receptors. American Association of Cancer Research Annual Meeting; 2004; Orlando (FL); 2004. p. Abstract 4957.
7. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000;12:611-20.
8. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and-independent pathways. Oncogene 2001;20:2122-33.
9. Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004;199:1041-52.
10. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev 2001;1:50-8.
11. Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer. Cancer Res 2004;64:7086-91.
12. Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 2007;67:2247-55.
13. Zhang X, Zhang L, Yang H, et al. c-Fos as a pro-apoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007;67:9425-34.
14. White SL, Belov L, Barber N, Hodgkin PD, Christopherson RI. Immunophenotypic changes induced on human HL60 leukaemia cells by 1α,25-dihydroxyvitamin D(3) and 12-O-tetradecanoyl phorbol-13-acetate. Leuk Res 2005;29:1141-51.
15. Han ZT, Tong YK, He LM, et al. 12-O-Tetradecanoylphorbol-13- acetate (TPA) - induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci U S A 1998;95:5362-5.
16. Herdegen T, Leah JD. Inducible and constitutive transcription factors in the mammalian nervous system: control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins. Brain Res Brain Res Rev 1998;28:370-490.
17. Altuwaijri S, Lin HK, Chuang KH, et al. Interruption of nuclear factor κB signaling by the androgen receptor facilitates 12-O- tetradecanoylphorbolacetate - induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res 2003;63:7106-12.
18. Engedal N, Korkmaz CG, Saatcioglu F. C-Jun N-terminal kinase is required for phorbol ester-and thapsigargin-induced apoptosis in the androgen responsive prostate cancer cell line LNCaP. Oncogene 2002;21:1017-27.
19. Garzotto M, Haimovitz-Friedman A, Liao WC, et al. Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res 1999;59:5194-201.
20. Cui XX, Chang RL, Zheng X, Woodward D, Strair R, Conney AH. A sensitive bioassay for measuring blood levels of 12-O-tetradecanoylphorbol-13- acetate (TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 2002;13:169-74.
21. Han ZT, Zhu XX, Yang RY, et al. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci U S A 1998;95:5357-61.
22. Strair RK, Schaar D, Goodell L, et al. Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 2002;8:2512-8.
23. Henttu P, Vihko P. The protein kinase C activator, phorbol ester, elicits disparate functional responses in androgen-sensitive and androgen-independent human prostatic cancer cells. Biochem Biophys Res Commun 1998;244:167-71.
24. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev 2005;208:126-40.
25. Vinson C, Myakishev M, Acharya A, Mir AA, Moll JR, Bonovich M. Classification of human B-ZIP proteins based on dimerization properties. Mol Cell Biol 2002;22:6321-35.
26. Zeng Y, Wu XX, Fiscella M, et al. Monoclonal antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006;28:421-30.
27. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007;251:146-57.
28. Humphreys RC. Activitating TRAIL death receptors with human agonist monoclonal antibodies. American Association for Cancer Research Annual Meeting; 2007; Los Angeles (CA); 2007.
29. Gohji K, Nakajima M, Boyd D, et al. Organ-site dependence for the production of urokinase-type plasminogen activator and metastasis by human renal cell carcinoma cells. Am J Pathol 1997;151:1655-61.
30. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006;12:1665-71.
31. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
32. Guan B, Yue P, Lotan R, Sun SY. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene 2002;21:3121-9.
33. American Cancer Society Cancer Fact & Figures. 2005 [cited; Available from: http://www.cancer.org].
34. Fall K, Garmo H, Andren O, et al. Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst 2007;99:526-32.
35. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res 2003;9:4537-45.
36. Kim H, Kim EH, Eom YW, et al. Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. Cancer Res 2006;66:1740-50.
37. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004;23:2554-8.
38. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11:77-84.
39. Jin H, Yang R, Fong S, et al. Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004;64:4900-5.
40. Ballestrero A, Nencioni A, Boy D, et al. Tumor necrosis factor-related apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing Jurkat cells. Clin Cancer Res 2004;10:1463-70.
41. Cretney E, Takeda K, Smyth MJ. Cancer: Novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 2007;39:280-6.
42. Marini P, Denzinger S, Schiller D, et al. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-54.
43. Abe K, Kurakin A, Mohseni-Maybodi M, Kay B, Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann N Y Acad Sci 2000;926:52-63.
44. Sheridan JP, Marsters SA, Pitti RM, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997;277:818-21.
45. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
46. Kelley RF, Totpal K, Lindstrom SH, et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;280:2205-12.
47. Lutz WK, Beland PE, Candrian R, Fekete T, Fischer WH. Dose-time response in mouse skin tumor induction by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoyl-phorbol-13-acetate. Regul Toxicol Pharmacol 1996;23:44-8.
48. Matsumoto K, Fujimoto M, Ito K, Tanaka H, Hirono I. Comparison of the effects of bilobol and 12-O-tetradecanoylphorbol-13-acetate on skin, and test of tumor promoting potential of bilobol in CD-1 mice. J Toxicol Sci 1990;15:39-46.